Skip to content

The new mechanism and clinical application of Huangqin in the treatment of sepsis

The new mechanism and clinical application of Huangqin in the treatment of sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000480
Enrollment
Unknown
Registered
2025-03-06
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Control group 3:Healthy people
Treatment group:Conventional treatment and baicalin capsules
Control group 2:Non-infected ascites patients

Sponsors

Chongqing Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Sepsis patients: 1) Meet both Western and TCM diagnostic criteria. 2) Age 18–85 years. 3) APACHE II score =15. 4) Informed consent signed by the patient or legal representative (for patients with impaired consciousness). non-infection ascites patients: 1) Ascites confirmed by abdominal ultrasound. 2) Age 18–85 years. 3) Informed consent signed. Healthy Individuals: 1) Age 18–85 years. 2) Normal liver and kidney function cardiac enzymes electrocardiogram blood tests C-reactive protein (CRP) and procalcitonin (PCT). 3) Informed consent signed.

Exclusion criteria

Exclusion criteria: Sepsis patients: 1) Failure to meet inclusion criteria. 2) Children menstruating females pregnant women or individuals with allergic constitutions. 3) Severe psychiatric disorders. 4) Inability to receive oral/nasogastric administration. 5) Use of Huangqin or related products within one month. 6) Refusal to participate or concurrent enrollment in similar trials. 7) Transferred patients with incomplete medical records. 8) Patients with any of the following risk factors: 1)Residents of long-term care facilities (e.g. nursing homes rehabilitation centers); 2)Severe underlying medical diseases (e.g. decompensated cirrhosis chronic kidney disease requiring regular dialysis COPD with chronic respiratory failure) 3)Hematologic disorders (e.g. chronic myeloid/lymphocytic leukemia myelodysplastic syndromes aplastic anemia) 4)Neurological or neurodevelopmental disorders (e.g. cerebral palsy epilepsy stroke intellectual disability moderate to severe development delay muscular dystrophy spinal cord injury) 5)Immunocompromised status (e.g. long-term use of immunosuppressive medications HIV infection malignancy-associated immunodeficiency) Non-infection ascites patients: Same as above with additional exclusion of patients with concurrent infections (e.g. pulmonary intra-abdominal urinary tract or bloodstream infections). Healthy individuals: Same as above with additional exclusion of individuals with chronic diseases or infectious history (e.g. diabetes hypertension coronary heart disease hepatitis B tuberculosis).

Design outcomes

Primary

MeasureTime frame
Patient survival rate at 28 days;

Secondary

MeasureTime frame
lactic acid;white cell;heart rate;blood transfusion;hospitalization expenses;TNFa;blood gas analysis;Duration of antibiotic use;Urine output;blood pressure;IL-6;D-Dimer;Duration of ICU stay;APACHE-II;IL-10;MODS;awareness;acute kidney injury;erythrocyte sedimentation rate;central venous pressure;C-reactive protein;ARDS;Duration of ventilator use;temperature;pulse;operation;etiological examination;Width of inferior vena cava;SOFA;breathe;Coagulation Function;Traditional Chinese Medicine Syndrome Score;mean arterial pressure;PCT;

Countries

China

Contacts

Public ContactFan Yi

Chongqing Traditional Chinese Medicine Hospital

16305978@qq.com13983665782

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026